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Toxoplasmosis: changes in epidemiology
Toxoplasma gondii is one of the most successful parasites. It 
shows a world-wide distribution, and toxoplasmosis can be 
life-threatening in immunocompromised patients and  fetus. 
However, there is no consensus on patient monitoring and 
treatment, and information on the impact on public health 
is scarce. Toxoplasma is a food-borne disease, but the risk 
factors related to cysts vary greatly between countries. 
“Therefore, prevention should be tailored to the local risk”, 
explained Prof. François Peyron, Institut de Parasitologie My-
cologie Médicale, Hôpital de la Croix-Rousse, Lyon, France. 
In South America, toxoplasmosis was demonstrated to be 
water-borne as well. As Prof. Peyron indicated, the type of 
route of infection matters greatly, as it has a dramatic effect 
on the choice of preventive measures. 
Another important epidemiological aspect is the declin-
ing seroprevalence. In France, seroprevalence rates dropped 
from 80 % in the 1960s to 37 % in 2010 (Figure 1), and they 
are expected to decrease further. The same trend has oc-
curred in the United States. Among the multifactorial caus-
es responsible for this development, those that stand out 
are improved hygiene and food consumption (e. g., indus-
trial freezing of meat), as well as information programs. De-
creases in seroprevalence affect the cost–benefit ratio of 
screening of pregnant women, rendering these programs 
more expensive. However, it is not known if declining sero-
prevalence is a world-wide phenomenon, as information 
from many countries is lacking. 
Virulence might depend on location
T. gondii shows a certain genetic diversity. Almost all Eu-
ropean strains belong to the type-II category, which have 
only low virulence. In South America, on the other hand, 
a  variety of atypical genotypes has been identified. “Im-
portantly, there is a link between clinical virulence and 
genotypes”, Prof. Peyron stated. South American strains 
tend to have  deleterious effects on the retina, which can 
cause ocular  lesions. “When gross malformations occurred 
in fetuses  in France, it was found that these infections had 
occurred through horse meat that was imported from 
South America.”
Toxoplasma gondii, cytomegalovirus, 
and Treponema pallidum infections in 
pregnancy: what’s new?
Congenital infections pose specific challenges in diagnostics and medical care. Infections acquired before  
or during pregnancy can extend to the fetus and lead to adverse outcomes, including fetal/ newborn death 
and malformation. Certain factors can affect the clinical course, such as the timing of an infection.  
At the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), experts discussed 
the diagnosis and treatment of congenital toxoplasmosis, cytomegalovirus (CMV) infection, and syphilis. 
According to the traditional pathophysiological knowl-
edge, life-long protective immunity is conveyed by the pres-
ence of toxoplasma cysts. Cysts are supposed to persist dur-
ing the entire life of the hosts. However, the dogma of “once 
infected, forever protected” is being challenged these days. 
“Serology can turn negative over time in congenitally infect-
ed people,” Prof. Peyron observed. The concept of the cyst 
lasting the entire life of the host should therefore be revis-
ited. 
Diagnosis in pregnant women
In antenatal diagnosis, important progress has been made 
over the last 20 years due to the use of amniocentesis and 
ultrasound. If amniocentesis is positive, treatment needs to 
be reinforced, because the fetus will be infected. Ultrasound 
can reveal gross abnormalities. In France, pregnancy termi-
nation is offered only in cases of abnormality detected by 
ultrasound. In the area of Lyon, this applied to less than 1 % 
of 2,500 documented maternal infections. “A diagnosis of 
toxoplasmosis in pregnant women therefore does not mean 
that pregnancy termination needs to be considered, at least 
not in Europe,” Prof. Peyron emphasized. 
In the first trimester, the probability of congenital infec-
tion with a positive polymerase chain reaction (PCR) test re-
sult obtained from the amniotic fluid is 64.0 %; in the sec-
ond trimester this rises to 95.4 %, and in the third trimester, 
to 98.2 % (Table 1) [1]. Here, it can be assumed that the fe-
tus is infected, and so the treatment and monitoring of the 
woman need to be adapted. If PCR testing is negative, the 
probabilities of congenital infection across the trimesters 
are 1.0 %, 10.0 % and 22.6 %, respectively. 
Established and new testing systems
Many diagnostic tests are available, with new kits entering 
the market also at present. Recently, serological testing has 
tended to focus on the use of recombinant antigens. “We 
should use a cocktail of recombinant antigens instead of 
only one or two, because we are targeting a very small 
epitope,” Prof. Peyron noted. “If genetic drift is present, test-
ing might miss the target.” By dating maternal infection, it 
is possible to differentiate acute from chronic infection. How-
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ever, interpretation of values within the grey zones of the 
kits is still a problem. When mass screening for IgG is per-
formed, false-positive results must be avoided. In IgM screen-
ing, conversely, the same applies to false-negative results. 
Avidity testing is helpful here, but it does not solve the prob-
lem entirely. A comparison of anti-toxoplasma IgG avidity 
kits was performed on 84 clinically defined sera, including 
the Architect, LIAISON®, and VIDAS kits. “For chronic infec-
tion, the majority of sera displayed high avidity, especially 
with LIAISON®,” Prof. Peyron said. Low avidity, on the other 
hand, does not necessarily relate to acute infection. 
A new diagnostic aspect arises from cellular immunity 
testing. “Cellular immunity has been disregarded in the clin-
ic for many years, because it was considered too complicat-
ed,” Prof. Peyron explained. “Fortunately, testing can be per-
formed now at low cost.” This technique, which can be very 
useful in pregnant women and newborns, is based on the 
specific secretion of interferon γ. Sensitivity and specificity 
are 96 % and 91 %, respectively, for the discrimination be-
tween infected and non-infected individuals. Other new 
tests that might be interesting for the screening of pregnant 
woman and newborns involve rapid diagnostic tests, saliva 
tests, and the Multiplexed Anti-Toxoplasma IgG, IgM and IgA 
Assay on plasmonic gold chips. Saliva testing is easy to per-
form and cheap, but sensitivity and specificity need to be 
improved. For the Multiplexed Assay, high rates of sensitiv-
ity and specificity of almost 100 % have been obtained [2]. 
Does toxoplasma infection influence  
behavior?
The potential for induction of behavioral changes by T. gon-
dii is a controversial topic. Discussions started when research-
ers observed that infected mice were attracted by cat urine, 
thus promoting the completion of the parasite life cycle, as 
these mice will be more likely to be eaten by cats. Manipu-
lation of the host might likewise occur in human beings. “It 
is assumed that cysts located in the brain cause local inflam-
mation that alters neutrotransmitters,” Prof. Peyron noted. 
Increased levels of dopamine have been found in infected 
mouse brains. Also, tyrosine hydroxylase, which induces do-
pamine, is encoded in the parasite genome. However, a re-
cent study identified no relationship between seropositivi-
ty and depression in 6,663 adults [3]. Prof. Peyron and his 
team also conducted a study using a questionnaire in 102 
congenitally infected adults, which did not show any behav-
ioral abnormalities [4].
Nonetheless, a possible social impact of T. gondii infec-
tion is conceivable. “Positive serology might prevent candi-
dates from applying for sensitive jobs, such as school bus 
drivers or airline pilots.” Also, a person accused in court might 
claim to be not guilty because of seropositivity. Prof. Peyron 
warned against disregarding the issue of toxoplasmosis and 
behavioral changes because of the danger of misuse, with 
a clear-headed view called for. Comprehensive studies need 
to be conducted, and stigmatization of seropositive people 
should be avoided.
Screening: the issue of cost-effectiveness
There is no consensus across countries with respect to tox-
oplasmosis screening of pregnant women, while at the same 
time, early diagnosis and effective treatment can make an 
enormous difference. The outcome is very good when an-
tenatal screening reveals the infection in time and treat-
ment is applied to the pregnant woman and to the new-
born. On the other hand, fetal loss and malformation can 
occur if no measures are taken. “Nowadays, we have strong 
evidence that antenatal treatment works,” Prof. Peyron 
stressed. Studies show that antenatal treatment is efficient 
when given within 4 weeks of maternal infection [5], and 
that it reduces the risk of transmission from mother to child 
[6]. In France, monthly screening was introduced in 1992, 
and fetal infections decreased afterwards [7]. Severe neu-
rological sequelae were reduced when treatment started 
during pregnancy [8]. 
“The challenge is how to reduce the costs of screening,” 
Prof. Peyron said. This might be achieved by new tests, like 
saliva tests, and also by information programs for pregnant 
women and care providers. The burden of disease should 
be evaluated for each country. Other measures include the 
implementation of information programs and reference 
centers, and the release of homogeneous guidelines, at least 
for Europe. As Prof. Peyron pointed out, it is important to at-
tract the attention of policymakers. “Congenital toxoplas-
mosis must not become a neglected disease.”
Indication 1st trimester 2nd trimester 3rd trimester
Pretest probability of congenital infection 2.2 % 23 % 56 %
Positive likelihood ratio 79 69 43
Probability of congenital infection with a positive 
test (90 % CI)
64 % (39 %–100 %) 95.4 % (91 %–100 %) 98.2 % (96.2 %–100 %)
Tab. 1:  Evolution of the probability of congenital infection according to positive PCR
Figure 1: Decreasing T. gondii seroprevalence in France over the last  
50 years
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Cytomegalovirus: watch out for primary  
infection in pregnancy
The overall birth prevalence of congenital CMV infection is 
0.64 %. In pregnant women, CMV infection can be primary 
or non-primary (i.e., as reactivation or reinfection). Trans-
mission to the fetus can occur in both cases. The rate of trans-
mission remains constant throughout pregnancy, with the 
risk being considerably higher in primary than in non-pri-
mary infection (40 %–50 % vs. 0.5 %–1 %). Accordingly, sig-
nificant handicaps at birth (e. g., mental retardation, bilat-
eral hearing loss) are seen more frequently in cases of pri-
mary infection (30 %–40 %, vs. 1 %–4 % in non-primary in-
fection) [9]. Altough, increasing observations demonstrate 
the risk for symptomatic infection at birth and sequelae, es-
pecially hearing loss, are similar upon primary and non-pri-
mary maternal CMV infection [10].
“Routine antenatal screening for CMV has never been rec-
ommended by any public health authority in any country,” 
said Prof. Tiziana Lazzarotto, Laboratory of Virology, Oper-
ative Unit of Clinical Microbiology, St. Orsola Malpighi Uni-
versity of Hospital, University of Bologna, Italy. Neverthe-
less, de-facto screening is performed through extensive test-
ing in Europe and Israel, and in some States in the United 
States. 
Prevention: prenatal treatment and hygienic 
intervention
No active CMV vaccines have been established yet. Passive 
immunization of pregnant women with CMV-specific hyper-
immune globulin treatment (e.g., Cytotect®, Cytogam®) is 
currently being investigated. In 2005, Nigro et al. showed 
that CMV-specific hyperimmune globulin is safe and might 
be effective in the treatment and prevention of congenital 
CMV infection [11]. However, these results were not con-
firmed by the randomized, double-blind, placebo-controlled, 
phase IIb CHIP study [12]. An open, single-arm phase III tri-
al has been investigating Cytotect® in pregnant women who 
have experienced seroconversion in the first trimester. Pub-
lication of these results is expected soon. A randomized, 
double-blind, placebo-controlled phase III study is assess-
ing Cytogam® in pregnant women with primary infection. 
This trial will be completed in December 2018. 
A controlled study provides evidence that behavioral 
measures and hygiene counselling of CMV-seronegative 
pregnant women can prevent maternal CMV infection [13]. 
The rates of seroconversion for the interventional group and 
the control group were 1.2 % and 7.6 %, respectively 
(p < 0.001). The number of newborns with congenital infec-
tion was 3 vs. 8. Young children are the primary source of 
CMV infection for pregnant women; the virus is shed in urine, 
saliva and tears. “Therefore, it is very important to offer in-
formation regarding hygienic and behavioral measures.”
Diagnosis of maternal infection
Maternal CMV infection can be ascertained in a reliable way 
by means of serological diagnosis if IgG and IgM screening 
tests are performed before 12 weeks of gestation. With re-
gard to the results, four categories are possible (Table 2). 
Depending on the combined results and the period of preg-
nancy, different measures are required. 
“It is very important to offer avidity testing before 16 
weeks of gestation, because during this period, the sensi-
tivity for the identification of an elevated risk of fetal trans-
mission is 100 %,” said Prof. Lazzarotto [14]. “After 21–22 
weeks, it decreases to 60 %.” A high avidity index before 16 
weeks of gestation indicates no current or recent primary 
infection, whereas a low or moderate avidity index suggests 
acute or recent primary infection. IgG avidity assays, such 
as LIAISON® CMV IgG Avidity, show high sensitivity and spec-
ificity. “Serological tests vary from one laboratory to anoth-
er,” Prof. Lazzarotto cautioned. “Therefore, the method used 
and its reference values must be carefully assessed.” The ref-
erence values for low, moderate and high avidity depend 
on the type of commercial kit. Moreover, false high avidity 
might be measured with automated test systems at very low 
CMV IgG levels. Virological diagnosis can complement the 
picture here; real-time PCR is used to identify viral DNA in 
body fluids (i. e., whole blood, saliva, urine). 
Prof. François Peyron
Institut de Parasitologie 
Mycologie Médicale, Hôpital 
de la Croix-Rousse, Lyon, 
France
What is the value of the toxoplasma IgM? 
Prof. Peyron: IgM is very important, because it is a marker 
of acute infection. At first IgM rises, which could be specific 
or not, and afterwards IgG levels rise. Then one can be sure 
that the woman has been recently infected. According to 
the timing of infection during pregnancy, the risk of fetal 
infection and the severity of infection vary considerably. 
How does avidity work?
Prof. Peyron: Avidity should be considered as an interest-
ing tool for dating infection. When the antibody response 
matures, the highly variable region of the antibody chang-
es, and the affinity to the specific epitope increases. With 
recent infection, IgG avidity is usually low, but many preg-
nant women keep low avidity for a long time. Therefore 
we only rely on high avidity to rule out recent infection. 
Also, avidity is kit sensitive.
How do toxoplasma screening policies vary between 
countries? 
Prof. Peyron: In France it is mandatory, while in Italy it is 
highly recommended, and in Germany, it depends on the
region. In the United States, there is no screening at all 
despite lobbying. Switzerland dropped screening 15 years 
ago. At that time, there was no clear evidence that ante-
natal treatment worked. Policymakers must ask themselves 
how much money they want to invest in order to treat one 
case. Cost–benefit studies are difficult, because the costs 
of child care in institutions must be considered as well. 
Information campaigns are very important. In France, we 
attempted to pass this task to obstetricians, but this did 
not work, because physicians usually do not have enough 
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Diagnosis of fetal infection
As Prof. Lazzarotto stressed, it is important to offer antena-
tal CMV diagnosis. This is reliable, with amniotic fluid being 
the most appropriate material. Fetal blood does not offer 
any additional diagnostic value; also, fetal blood assessment 
carries a high risk of fetal demise and should therefore be 
avoided. Prenatal diagnosis is indicated 6–8 weeks after the 
onset of maternal infection. Amniocentesis should be per-
formed at 20–21 weeks of gestation. The fetus excretes CMV 
via urine into the amniotic fluid, and a sufficient amount of 
fetal diuresis is produced only at that time. “Amniocentesis 
must be accompanied by ultrasound examination and coun-
selling,” Prof. Lazzarotto said. The sensitivity, specificity, and 
predictive values of PCR tests for CMV-DNA detection in am-
niotic fluid are very high. In the newborn, the gold standard 
of diagnosis is real-time PCR on urine or saliva. 
Syphilis: a disease is back
Treponema pallidum is the causative pathogen of syphilis, 
which remains a public health concern. In 2011, the World 
Health Organisation (WHO) estimated that 36.4 million adults 
are infected worldwide. At the same time, a successful test 
for this chronic bacterial infection has been available since 
the early 1900s, and penicillin treatment was introduced in 
the 1940s. “After the introduction of penicillin, there was a 
marked decline in reported syphilis cases,” noted Dr. Pas-
cale Huynen, Clinical Microbiology Department, University 
Hospital of Liège, Belgium. “Over the last decade, however, 
this rate increased again, notably in Russia, China and the 
United States.” In developed countries, increases in syphilis 
rates are seen mainly for the high-risk groups, such as the 
homosexual male population. 
Congenital syphilis is based on transplacental transmis-
sion mainly during the second half of pregnancy or at birth 
[15]. The risk is maximal in cases of recent maternal infec-
tion, within the previous year. Also, the transmission rate de-
pends on the stage of maternal syphilis: it is 60 % to 80 % if 
primary or secondary syphilis is present. In late syphilis, the 
risk decreases to 8 %. “Approximately 1.5 million pregnant 
women are infected with active syphilis every year”, report-
ed Dr. Huynen [16, 17]. “Half of them remain untreated, which 
results in adverse outcomes.” These include early fetal loss, 
stillbirth, perinatal death, prematurity or low birth weight, 
and serious neonatal infection, which is analogous to the 
secondary stage of acquired syphilis. Clinical signs of con-
genital syphilis at birth include hepatosplenomegaly, ab-
normal facial features, edema, abdominal distension, pallor, 
skin lesions, and fever. However, approximately half of in-
fected newborns are asymptomatic. 
Categories Period of pregnancy What does this mean? What should be done?
IgG- 
IgM-
Just before pregnancy or during 
pregnancy
Non-immune women.  
High risk of acquiring primary infection








Before or during pregnancy
Indicative of primary infection or IgM 
false-positive result
Serological testing performed in the 
same laboratory after 10–15 days
IgG+ 
IgM+
Before 16 weeks of gestation
Indicative of 
● Active infection 
● Primary infection 
● Non-primary infection
Advanced diagnosis 
➝ avidity IgG test
Tab. 2:  Primary CMV infection in pregnant women: interpretation and measures to be taken
Prof. Tiziana Lazzarotto
Laboratory of Virology, 
Operative Unit of Clinical 
Microbiology, St. Orsola 
Malpighi University of Hos-
pital, University of Bologna, 
Bologna, Italy
Are automated tests useful for high-volume routine? 
Prof. Lazzarotto: Yes. At my hospital, the microbiological 
laboratory performs CMV-testing on 150 samples a day. This 
is impossible without automated systems. Also, they are 
important regarding the prevention of human errors. The 
bar code is recognized by the system, and the history of the 
vial is fully traceable. Interpretation by laboratory technicians, 
which can be wrong due to misreading, is not necessary.  
The Nigro study results have not been confirmed, and the 
CMV vaccine has been demonstrated not to be successful. 
Are there any other drugs in development with promising 
results?
Prof. Lazzarotto: Some international companies are current-
ly working on a new vaccine. The previous vaccine included 
only one glycoprotein; this was not enough in terms of effi-
cacy. This new vaccine includes other glycoproteins and 
further proteins involved in the pathogenesis of CMV. At 
present, antiviral treatment is not available in pregnancy. 
Foscavir and cidofovir are nephrotoxic and cannot be admin-
istered in pregnant women. For ganciclovir, we do not have 
strong evidence that it crosses the placenta. Another problem 
relating to ganciclovir is a decrease in fetal-fertility, which 
was demonstrated in the animal model. 
Which aspects would you deem especially important for 
daily practice? 
Prof. Lazzarotto: Even in the absence of preventive treatment 
or vaccines, we can resort to hygienic measures. It was shown 
that behavioral measures are very effective for the prevention 
of CMV. The education of pregnant women is therefore very 
important. Also, we have the possibility to treat the newborn. 
Randomized controlled trials established that it is mandato-
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Congenital syphilis is particularly prevalent in developing 
countries. According to WHO estimates, 96 % of maternal 
syphilis infections and 98 % of adverse outcomes occur in 
low-income and middle-income areas. In Europe, the fig-
ures pertaining to congenital syphilis have remained stable 
over the last 10 years (Figure 2) [18], but it is suspected that 
there is considerable underreporting. 
Diagnostic options
Syphilis can be identified via direct diagnosis from the ulcer 
or lesion in the pre-serological phase, or via detection of an-
tibodies to T. pallidum in serum, cerebrospinal fluid (CSF), or 
whole blood. Direct diagnosis is performed using dark-field 
microscopy, antigen detection via fluorescence microscopy, 
and molecular biology. The molecular biology approach has 
high sensitivity and specificity, and it can also be performed 
on amniotic fluid and material from the placenta and um-
bilical cord. However, serology is the main laboratory tool 
for screening and follow-up of treatment [19]. Also, serolo-
gy is the only method that can identify latent syphilis.
A wide range of tools is available. Non-treponemal tests 
provide information on the activity of the disease, while tre-
ponemal tests are more specific, and can thus be used to 
confirm reactive non-treponemal test results. However, un-
like the non-treponemal tests, treponemal tests cannot dis-
tinguish between active and previously treated infection. 
“A combination of the two test types is recommended,” Dr. 
Huynen said. No serological test that can discriminate be-
tween syphilis and non-venereal treponematosis has been 
established to date. 
Non-treponemal and treponemal tests
Non-treponemal tests, such as Rapid Plasma Reagin (RPR)/ 
Veneral Disease Research Laboratory (VDRL) tests have the 
advantage of being inexpensive and quantitative. “They are 
the only tests recommended to follow the course of the dis-
ease during and after treatment,” noted Dr. Huynen. Test-
ing is simple and rapid, and can also be performed on CSF 
(i. e., for the diagnosis of neurosyphilis). As the tests are not 
specific for T. pallidum, false-positive results due to cross-re-
activity represent the main limitation. The specificity is 93 % 
to 98 %. 
Treponemal tests include fluorescent treponemal anti-
body absorbed test (FTA-Abs), Treponema pallidum hemag-
glutination assay (TPHA)/ Treponema pallidum particle ag-
glutination assay (TPPA), enzyme immunoassays (EIAs)/ 
chemiluminescent immunoassays (CLIAs)/ micro-bead im-
munoassays (MBIAs), rapid tests, and Western blotting. TPHA 
and TPPA are specific for T. pallidum, and are quantitative 
for serum and CSF. The sensitivity ranges from 85 % to 100 %, 
and specificity from 98 % to 100 %. “Reactivity usually per-
sists over the lifetime, even after treatment,” Dr. Huynen ex-
plained. The fluorescent treponemal antibody absorbed test 
is based on immunofluorescence. It has high sensitivity 
(70 %–100 %) and specificity (94 %–100 %), but it remains 
positive even after treatment. Indications include assess-
ment of congenital syphilis (IgM) and confirmation of recent 
infection demonstrated with RPR/TPHA. Western blotting 
is a confirmatory test that can contribute to the diagnosis of 
congenital syphilis. 
Rapid tests are based on immunochromatography, and 
these can be used in developing countries, as they are che-
ap and require only minimal training. A small amount of who-
le blood collected by a finger prick is sufficient. However, the 
test cannot distinguish between active and past infection. 
“More than 20 tests are available,” Dr. Huynen said. “Most of 
them exhibit high sensitivity and specificity.”
What can enzyme immunoassays do?
In recent years, enzyme immunoassays (i. e., EIA/ CLIA/ MBIA) 
have been developed for the screening of syphilis. Their sen-
sibility and specificity is comparable to those of other tests 
(82 %–100 %, 97 %–100 %, respectively), and they allow for 
IgM and/or IgG detection. IgM assessment is very sensitive 
in early infections and congenital infections. As enzyme im-
munoassays are qualitative, their only indication is screen-
ing. Test results do not correlate with disease activity, and 
they remain positive even after treatment, except in 
15 %–25 % of patients who are treated early (primary stage). 
Enzyme immunoassays offer advantages over trepone-
mal tests because they can be automated, allowing for high 
throughput, with diminished laboratory occupational haz-
ard. Manual pipetting is not necessary, and false-negative 
results due to the prozone reactions are avoided. 
LIAISON® was the first CLIA available for T. pallidum antibody 
screening (for total antibodies) of serum and CSF. This sys-
tem uses the TpN17 recombinant specific T. pallidum anti-
gen. “It has been well demonstrated in several studies, but 
also in our routine practice, that these tests exhibit high sen-
sitivity and specificity of more than 99 %,” Dr. Huynen re-
ported [20, 21]. LIAISON® XL is fully automated, and offers 
the advantages of a random-access system and full tracea-
bility. The reagents are also stable over long periods of time 
(≥ 4 weeks). 
Recommendations for follow-up
Different algorithms are used for serological screening and 
diagnosis. These include the algorithm provided by the 
American Centers for Disease Control and Prevention, and 
Figure 2: Congenital syphilis in Europe: reported cases from 2003 to 2012
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the recommendations by WHO and European Guidelines on 
the Management of Syphilis 2014 (Figure 3) [22]. In this case 
a single treponemal test is used as screening. For confirma-
tion both treponemal and non treponemal tests are need-
ed to assess if the infection is active or not. If discordant re-
sults are obtained, then another treponemal test such as 
western blot can be used. Full interpretation of the test re-
sults requires a synopsis of different tests (Table 3). For fol-
low-up, quantitative testing (e. g., RPR) is recommended 
every 2 to 3 months. If 4-fold decreases in titers occur, it can 
be assumed that the treatment has worked. Increasing ti-
ters, on the other hand, hint at reinfection or reactivation. 
At birth, the same serological profile (IgG) is present in 
the mother and newborn. IgM detection can be performed 
to highlight antibody production by the newborn. Quanti-
tative RPR serologic titers that are 4-fold higher in the baby 
than the mother are highly indicative of congenital syphi-
lis. For the follow-up of an infected child, RPR testing is rec-
ommended every 2 to 3 months until the test becomes se-
ronegative. “A neonate with negative RPR born to a sero-
positive mother should be retested at 3 months to rule out 
incubating congenital syphilis at birth,” Dr. Huynen ex-
plained. Importantly, treponemal tests should not be used 
in newborns, because passive transfer of maternal IgG might 
persist for more than 15 months. 
Treatment of the mother and the newborn
“In pregnancy, all patients with a positive test should be 
treated,” Dr. Huynen emphasized. Penicillin G is the only 
known effective drug for preventing maternal transmission 
and treating fetal infection. Benzathine penicillin G is rec-
ommended at a dose of 2.4 million units intramuscularly. 
Pregnant women should receive penicillin appropriate to 
their stage of infection. Primary, secondary and early latent 
syphilis call for a single dose, while three doses should be 
administered for the other stages. Neurosyphilis requires 
treatment for 10 to 14 days. 
Neonates born to women showing reactive serologic tests 
for syphilis should be examined thoroughly for evidence of 
congenital syphilis. In cases of proven, highly probable, or 
possible congenital syphilis, either aqueous crystalline pen-
icillin G (100,000-150,000 units/kg/day, intravenously) or pro-
caine penicillin G (50,000 units/kg/day, intramuscularly) 
should be applied for 10 days. If congenital syphilis is less 
likely, a single dose of benzathine penicillin G (50,000 units/
kg, intramuscularly) is indicated. Neonates who show per-
sistent RPR titers by 6 to 12 months should be re-evaluated 
and treated with 10 days of penicillin G. Also, CSF examina-
tion should be included in the work-up. 
Prevention of congenital syphilis is  
worthwhile
Worldwide, congenital syphilis is responsible for the death 
of more than one million babies every year. As syphilis in-
fection can be asymptomatic, detection is often delayed. 
“Unlike many neonatal infections, congenital syphilis is a 
preventable disease,” Dr. Huynen pointed out. Infected 
mothers should be identified and treated before the mid-
dle of the second trimester. “Serological screening in all preg-
nant women – not only in those being perceived as a high-
risk group – and treatment are feasible, even in low-resource 
settings,” Dr. Huynen said. Information on the importance 
of treating the women, the newborn, and the partners should 
be provided to the patients. 
For pregnant women, screening is recommended at the 
first prenatal visit. In the case of increased risk, testing should 
be repeated at 28 weeks of gestation and at delivery. Infor-
mation concerning risk behaviors and treatment of sex part-
ners should be obtained to assess the risk of reinfection. For 
newborns, routine screening is not recommended. If they 
are born to mothers with syphilis, quantitative non-trepone-
Enzyme immunoassays  
(EIA/CLIA)*
Rapid Plasma Reagin (RPR)
Treponema pallidum particle 
agglutination assay (TPPA)
Interpretation
Positive Negative** Positive Primary syphilis OR treated  
syphilis OR latency
Positive Positive** Negative Primary syphilis OR false 
positive result
Positive Positive Positive
Active syphilis OR treated  
syphilis (RPR < 32)
*EIA, enzyme immuno assays; CLIA, chemiluminescent immunoassays 
** FTA-Abs IgM if active infection suspected
Tab. 3: Interpretation of the results of syphilis testing
Figure 3: Diagnostic algorithm according to WHO 2008/ European Guidelines on the  
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Special
mal testing is called for. “No mother or newborn should leave 
the hospital without determination of the maternal serolog-
ical status at least once during pregnancy, and again at de-
livery if the risk is increased,” Dr. Huynen stated.
Screening and treatment for syphilis in pregnant women 
are cost-effective antenatal interventions, and are strongly 
promoted by the WHO, as large reductions in congenital 
syphilis are feasible. Between 2008 and 2012, a 33 % de-
crease in maternal infections and adverse pregnancy out-
comes was noted. India alone represented 37 % of this de-
cline due to improvements in data quality and efforts to-
wards the control of sexually transmitted infections. “This 
is a promising sign that efforts to control syphilis in preg-




Hospital of Liège, Belgium
How do you rate the development of the syphilis cases 
diagnosed in your laboratory?
Dr. Huynen: The incidence used to be low in the past, but 
now the numbers are increasing. Our hospital contains a 
large center for AIDS patients, and another center for hep-
atitis C patients. Also, there are refugee centers in the 
vicinity of the hospital. 
How would you judge the performance of the LIAISON® 
Treponema assay as used in your laboratory?
Dr. Huynen: We use this test only for screening, because 
it is semi-quantitative. It cannot be used for the follow-up. 
It is a very sensitive test; for early pregnancy, the results 
show that the test is surprisingly sensitive. We had one 
case of a patient in whom only the LIAISON® TP screening 
test and the PRP were positive. The other treponemal tests 
were negative. The clinician was sure that the patient did 
not have syphilis, but one week later the diagnosis was 
confirmed. Also, the LIAISON® TP test is highly specific at 
higher antibody levels. At very low results close to the 
cut-off, false-positive results can occur, and so the testing 
of a second serum sample is required to confirm the diag-
nosis. However, we only once observed positive results 
with the LIAISON® screening that turned out to be negative 
with TPHA testing. This was a patient who was infected 
with hepatitis C and HIV. Six weeks later the syphilis test 
result was highly positive with both treponemal tests and 
RPR. In some cases in whom the interpretation of the TPHA 
results is difficult, we use LIAISON® TP screening of the CSF 
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ide tify high-risk patients,” explained Prof. Vincent C. Emery, 
PhD, Department of Virology, University College Lond n, Eng-
land. “In the post-transplant phase, the virus replication has to be 
detected directly.” According to the guidelines, pre-emptive the-
rapy is most appropriate for patients at low or intermediate risk 
for CMV disease, whereas universal prophylaxis is the recommen-
ded strategy in high-risk patients. (12, 13) Both measures effec-
tively reduce the development of CMV disease by minimizing the 
direct effects of MV in the crucial 100-day post-transplantation 
p riod. (14) Pre-em tive therapy requires frequ nt moni ori g. “A 
universal DNA standard as a cut-off to initate pre-emptive treat-
ment is missing, but would allow the global comparison of data,” 
Prof. Emery pointed out.
In high-risk patients, prophylaxis should be given for 3 to 6 
months, depending on immunosuppression and the type of trans-
plantation. However, late disease remains an issue. A study com-
paring 100-day administratio  of valganciclovir with 200-day ad-
ministration of the same drug showed a significantly smaller 
proportion of patients with confirmed CMV disease at 12 months 
in the group that had been treated for the longer period of time 
(16.1 % vs. 36.8 %; p < 0.0001). (15) Also, the incidence of viremia 
was significantly reduced in the 200-day group (37.4 % vs. 50.9 %; 
p = 0.0149). “It would appear that a prophylaxis for 200 days does 
reduce infections and CMV syndrome quite substantially, at least 
in the high-risk setti g,” Prof. Emery said. “Whether this also ap-
plies to other settings remains to be seen.”
For the treatment of CMV disease, the current guidelines re-
commend intravenous ganciclovir (5 mg/kg bid) or valganciclovir 
(900 mg bid). Treatment should continue until eradication of the 
viremia, and secondary prophylaxis can be considered. n
 Dr. Judith Moser
Source: 20th european Congress of Clinical Microbiology and Infectious  
Diseases (eCCMID), 10th–13th april, Vienna
case that was examined 20 weeks after infection and had an avi-
dity index value close to the high avidity reference. None of the 
110 samples in group 2 (infection duration > 3 months) showed 
any low IgG avidity. In group 3, the results of all of the 358 samp-
les indicated high avidity, which was consistent with the known 
past infection in these women. Conversely, IgG avidity was not 
applicable in ll of the 123 samples tested in group 4, whi h were 
negative for both IgG and IgM. Overall, the findings indicated a 
test specifity of 100 %.
One of the aims of the study was to determine whether the in-
dex value above or equal to 0.3 obtained with the LIAISON® CMV 
IgG avidity excludes acute primary infection. Indeed, samples 
from infected women obtained earlier than 16 weeks after infec-
tion showed mainly low and some moderate avidity below this 
cut-off. “A high IgG avidity with a LIAISON® Avidity Index of 0.3 or 
beyond is a valuable tool for the exclusion of recently acquired 
primary infections in pregnant women and significantly decrea-
ses the necessity for follow-up testing,” Dr. Lazzarotto concluded.
Impact of MV after organ transplant tion
The success of solid organ transplantation can be adversely influ-
enced by CMV infections. Direct and indirect effects of CMV are 
seen in this context (Tab. 5). Therapeutic approaches to control vi-
rus replication include prophylaxis and pre-emptive therapy. Pro-
phylaxis, which can be conducted either in a universal manner or 
as a focus on high-risk patients, eliminates both the direct and in-
direct effects of infection. Pre-empt  therapy is initiat d based 
on vir l gic markers, thus mi imizing drug exposure. This ap-
proach has the drawback that it might not eliminate the indirect 
effects of CMV.
“Guidelines for the management of CMV infections following 
transplantation recommend pre-transplant serological assays to 
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